Paired analysis of P-glycoprotein expression and function in patients with acute myeloid leukemia at diagnosis and relapse/refractory disease
| . | At diagnosis . | At relapse and/or refractory disease . | P value . |
|---|---|---|---|
| MDR1 | |||
| MRK16 | |||
| Median | 2.16 | 1.83 | .14 |
| Range | 1.22-7.65 | 1.02-5.55 | |
| N | 27 | ||
| MRK16/CD34+ | |||
| Median | 2.77 | 2.28 | 1.00 |
| Range | 1.52-9.27 | 1.46-9.6 | |
| N | 11 | ||
| UIC2 | |||
| Median | 2.37 | 1.74 | .22 |
| Range | 1.47-12.3 | 0.99-6.39 | |
| N | 25 | ||
| UIC2/CD34+ | |||
| Median | 3.5 | 2.42 | .07 |
| Range | 1.51-26.6 | 0.86-7.34 | |
| N | 8 | ||
| PSC/Rho | |||
| Median | 1.13 | 1.10 | .26 |
| Range | 0.87-2.11 | 0.81-2.19 | |
| N | 27 | ||
| PSC/Rho/CD34+ | |||
| Median | 1.43 | 1.22 | .39 |
| Range | 0.98-2.7 | 0.82-3.26 | |
| N | 12 |
| . | At diagnosis . | At relapse and/or refractory disease . | P value . |
|---|---|---|---|
| MDR1 | |||
| MRK16 | |||
| Median | 2.16 | 1.83 | .14 |
| Range | 1.22-7.65 | 1.02-5.55 | |
| N | 27 | ||
| MRK16/CD34+ | |||
| Median | 2.77 | 2.28 | 1.00 |
| Range | 1.52-9.27 | 1.46-9.6 | |
| N | 11 | ||
| UIC2 | |||
| Median | 2.37 | 1.74 | .22 |
| Range | 1.47-12.3 | 0.99-6.39 | |
| N | 25 | ||
| UIC2/CD34+ | |||
| Median | 3.5 | 2.42 | .07 |
| Range | 1.51-26.6 | 0.86-7.34 | |
| N | 8 | ||
| PSC/Rho | |||
| Median | 1.13 | 1.10 | .26 |
| Range | 0.87-2.11 | 0.81-2.19 | |
| N | 27 | ||
| PSC/Rho/CD34+ | |||
| Median | 1.43 | 1.22 | .39 |
| Range | 0.98-2.7 | 0.82-3.26 | |
| N | 12 |
For P-gp expression, the monoclonal antibodies MRK 16 and UIC2 were used; for P-gp function, the PSC/Rho 123 retention ratio was used. In samples with greater than 10% CD34 expression, the variables were also evaluated in the CD34+ subfraction of the blasts. TheP values indicate the differences between diagnosis and relapse/refractory disease.